Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 453-458

  Philpott, Andrew C ^a   Hubacek, Jaroslav ^b   Sun, Yichun C ^b   Hillard, Darlene ^b   Anderson, Todd J ^b  

^a LYELL MCEWIN HOSPITAL   (Australia)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

CRP; Endothelial function; FMD; Niacin; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RELEASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TONOMETRY; TREATMENT DURATION;

AGED; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOALPHALIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; NIACIN; PYRROLES;

EID: 84872375428     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.067     Document Type: Article

References (31)

1. Fleisher L.N., Tall A.R., Witte L.D., et al. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982, 257:6653-6655.
2. Yuhanna I.S., Zhu Y., Cox B.E., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001, 7:853-857.
3. Noor R., Shuaib U., Wang C.X., et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 2007, 192:92-99.
4. Nissen S.E., Tuzcu E.M., Brewer H.B., et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253-1263.
5. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
6. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
7. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
8. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
9. Yan R.T., Anderson T.J., Charbonneau F., et al. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005, 45:1980-1986.
10. Roifman I., Sun Y.C., Fedwick J.P., et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009, 7:175-182.
11. Philpott A.C., Lonn E., Title L.M., et al. Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors. Am J Cardiol 2009, 103:1610-1615.
12. Mitchell G.F., Vita J.A., Larson M.G., et al. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation 2005, 112:3722-3728.
13. Warnholtz A., Wild P., Ostad M.A., et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 2009, 204:216-221.
14. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26:1235-1241.
15. Yeboah J., Crouse J.R., Hsu F.C., et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007, 115:2390-2397.
16. Yeboah J., Folsom A.R., Burke G.L., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
17. Anderson T.J., Charbonneau F., Title L.M., et al. Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation 2011, 123:163-169.
18. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488-493.
19. Anderson T.J., Elstein E., Haber H., et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000, 35:60-66.
20. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
21. Lee J.M., Robson M.D., Yu L.M., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54:1787-1794.
22. Kuvin J.T., Ramet M.E., Patel A.R., et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002, 144:165-172.
23. Benjo A.M., Maranhao R.C., Coimbra S.R., et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis 2006, 187:116-122.
24. Sorrentino S.A., Besler C., Rohrer L., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010, 121:110-122.
25. Westphal S., Borucki K., Taneva E., et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007, 193:361-365.
26. Tunaru S., Kero J., Schaub A., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9:352-355.
27. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin. Am J Cardiol 2008, 101:20B-26B.
28. Nofer J.R., Walter M., Kehrel B., et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998, 18:861-869.
29. Toth P.P. Activation of intracellular signaling systems by high-density lipoproteins. J Clin Lipidol 2010, 4:376-381.
30. Ostad M.A., Eggeling S., Tschentscher P., et al. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009, 205:227-232.
31. Goldberg R.B., Jacobson T.A. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008, 83:470-478.